This report was first published by Endpoints News. To see the original version, click here
AstraZeneca is already delivering on its $15 billion commitment to China with a $1.2 billion upfront pact with CSPC Pharmaceutical, spanning eight drug programs and multiple platform technologies.
On Thursday, the UK pharma giant disclosed plans to bolster its manufacturing and drug R&D in China, the hottest region of biomedical innovation, by committing $15 billion through 2030.
您已阅读17%（471字），剩余83%（2250字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。